Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction

Pharmacotherapy

Volumn 26, Issue 4, 2006, Pages 452-460

  Kiser, Tyree H ^a   Fish, Douglas N ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Anticoagulation; Bivalirudin; Bleeding; Direct thrombin inhibitor; Dosage; Platelet; Thrombus

Indexed keywords

ARGATROBAN; HEPARIN; HIRULOG; LEPIRUDIN; WARFARIN;

ADULT; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTINUOUS HEMOFILTRATION; CRITICALLY ILL PATIENT; DIALYSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MALE; PARTIAL THROMBOPLASTIN TIME; RENAL REPLACEMENT THERAPY; THROMBOSIS;

ADULT; AGED; ANTICOAGULANTS; COHORT STUDIES; CRITICAL ILLNESS; FEMALE; HEPARIN; HIRUDINS; HUMANS; INTENSIVE CARE UNITS; KIDNEY DISEASES; LIVER DISEASES; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; THROMBIN; THROMBOCYTOPENIA;

EID: 33645694284     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.4.452     Document Type: Article

References (32)

1. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
2. Schmitt BP, Adelman B. Heparin-associated thrombocytopenia: a critical review and pooled analysis. Am J Med Sci 1993;305:208-15.
3. Girolami B, Prandoni P, Stefani PM, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 2003;101:2955-9.
4. Prandoni P, Siragusa S, Girolami B, Fabris F. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood 2005;106:3049-54.
5. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001;344:1286-92.
6. Nand S, Wong W, Yuen B, Yetter A, Schmulbach E, Gross Fisher S. Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol 1997;56:12-16.
7. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126(suppl 3):S311-37.
8. Verma AK, Levine M, Shalansky SJ, Carter CJ, Kelton JG. Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy 2003;23:745-53.
9. Wester JP, Haas FJ, Biesma DH, Leusink JA, Veth G. Thrombosis and hemorrhage in heparin-induced thrombocytopenia in seriously ill patients. Intensive Care Med 2004;30:1927-34.
10. Mann MJ, Tseng E, Ratcliffe M, et al. Use of bivalirudin, a direct thrombin inhibitor, and its reversal with modified ultrafiltration during heart transplantation in a patient with heparin-induced thrombocytopenia. J Heart Lung Transplant 2005;24:222-5.
11. Warkentin TE, Koster A. Bivalirudin: a review. Expert Opin Pharmacother 2005;6:1349-71.
12. Fox I, Dawson A, Loynds P, et al. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost 1993;69:157-63.
13. Nand S. Hirudin therapy for heparin-associated thrombocytopenia and deep venous thrombosis. Am J Hematol 1993;43:310-11.
14. Francis J, Drexler A, Gwyn G, Moroose R. Successful use of bivalirudin in the treatment of patients suspected, or at risk of, heparin-induced thrombocytopenia [abstr]. Blood 2004;103:4077.
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
16. Kiser TH, Jung R, MacLaren R, Fish DN. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia. Pharmacotherapy 2005;25:1736-45.
17. Robson R, White H, Aylward P, Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin Pharmacol Ther 2002;71:433-9.
18. Irvin W, Sica D, Gehr T. Pharmacodynamics (PD) and kinetics (PK) of bivalirudin (BIV) in renal failure (RF) and hemodialysis (HD) [abstr]. Clin Pharmacol Ther 1999;65:202.
19. Gosselin RC, Dager WE, King JH, et al. Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values. Am J Clin Pathol 2004;121:593-9.
20. Stephens JL, Koerber JM, Mattson JC, Smythe MA. Effect of lepirudin on the international normalized ratio. Ann Pharmacother 2005;39:28-31.
21. Warkentin TE. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. Thromb Res 2003;110:73-82.
22. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-43.
23. Lewis BE, Wallis DE, Leya F, Bursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003;163:1849-56.
24. Lubenow N, Eichler P, Lietz T, Farner B, Greinacher A. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. Blood 2004;104:3072-7.
25. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999;99:73-80.
26. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-associated thrombocytopenia study (HAT) investigators. Circulation 1999;100:587-93.
27. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.
28. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502-7.
29. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999;106:629-35.
30. Lubenow N, Eichler P, Greinacher A. Results of a large drug monitoring program confirms the safety and efficacy of Refludan (lepirudin) in patients with immune-mediated heparin-induced thrombocytopenia [abstr]. Blood 2002;100(suppl 1):502a.
31. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000;96:846-51.
32. Favaloro EJ, Bonar R, Sioufi J, et al. An international survey of current practice in the laboratory assessment of anticoagulant therapy with heparin. Pathology 2005;37:234-8.